DiaMedica Therapeutics Inc (DMAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $474.29M
Last updated: Nov 17, 2026 at 11:03 AM ET
DiaMedica Therapeutics Inc (DMAC) Stock Forecast
Analysts expect DiaMedica Therapeutics (DMAC) to earn -$0.81 per share in the fiscal year ending Dec 31, 2026. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.81
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.75
- EPS consensus
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.81 | -$0.88 to -$0.76 | 4 |
| Dec 31, 2027 | -$0.75 | -$0.98 to -$0.59 | 4 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.23 | -$0.25 to -$0.20 | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.83.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.81 | -$0.81 | -$0.81 | -$0.81 | -$0.83 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.75 | -$0.81 | -$0.81 | -$0.81 | -$0.88 | N/A |
Frequently Asked Questions About DMAC
What is the DMAC stock forecast?
Consensus analyst estimates put DiaMedica Therapeutics's EPS at -$0.81 for the fiscal year ending Dec 31, 2026. The consensus rating from 5 analysts is Buy.
How do analysts rate DMAC stock?
Of 5 analysts covering DiaMedica Therapeutics, 0 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DMAC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.81, with estimates from -$0.88 to -$0.76 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.75, with estimates from -$0.98 to -$0.59 from 4 analysts.
How many analysts cover DMAC?
5 analysts rate DiaMedica Therapeutics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DMAC pages: Overview, Earnings, Forecast, Financials, Competitors